Anti-SARS-CoV-2 Spike and Nucleocapsid proteins Monoclonal Antibodies for Detection and Treatment and Detection
Updated time: 2020-07-08 20:50:45
Anti-SARS-CoV-2 Spike and Nucleocapsid proteins Monoclonal Antibodies for Detection and Treatment and Detection
Docket Number
10T-1090515
Announcement Date
2020-05-19
IP Status
Know-how
Abstract
After immunization with spike and nucleocapsid proteins of SARS-CoV-2, the hybridoma cells were prepared and screened by ELISA. Currently, we have obtained several high binding affinities and specificities monoclonal antibodies against SARS-CoV-2 that can be used to develop rapid diagnostic reagents and therapeutic antibodies.
Technological Advantages
- Antibodies are highly specific and sensitive.
- Anti-spike antibodies have neutralizing effects for therapy.
Applications of Technology
- SARS-CoV-2 rapid detection.
- SARS-CoV-2 therapy.
Inventor
Han-Chung Wu
Contact person
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Anti-SARS-CoV-2 Spike and Nucleocapsid proteins Monoclonal Antibodies for Detection and Treatment and Detection